NPCE Stock Summary and Trading Ideas (Neuropace | NASDAQ:NPCE)

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Neuropace trades on the NASDAQ stock market under the symbol NPCE.

As of March 3, 2025, NPCE stock price declined to $11.81 with 195,039 million shares trading.

NPCE has a beta of 0.31, meaning it tends to be less sensitive to market movements. NPCE has a correlation of 0.00 to the broad based SPY ETF.

NPCE has a market cap of $367.02 million. This is considered a Small Cap stock.

Last quarter Neuropace reported $21 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.08.

In the last 3 years, NPCE traded as high as $18.15 and as low as $1.22.

The top ETF exchange traded funds that NPCE belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

NPCE has underperformed the market in the last year with a return of -29.5%, while SPY returned +16.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in NPCE shares. However, NPCE has outperformed the market in the last 3 month and 2 week periods, returning +15.2% and -4.1%, while SPY returned -2.2% and -4.3%, respectively. This indicates NPCE has been having a stronger performance recently.

NPCE support price is $12.26 and resistance is $13.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NPCE shares will trade within this expected range on the day.